Please Wait a Moment
X

Articles

27Jul

Bio-Rad Geenius HIV 1/2 Implementation

27 Jul, 2020 | Return|

CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.

Read all about it on the Communication page by clicking this link: Communications

 

 

Related

FDA Guidance ZIKV Testing Strategy Webinar

On Wednesday August 15, 2018 at 11:00AM PDT, we will be hosting a webinar regarding the changes to F...

Read More >

World Patient Safety Day 2020

The COVID-19 pandemic has unveiled the huge challenges and risks health workers are facing globally ...

Read More >

CTS Charlotte Lab Implements WNV Testing on the Panther

CTS Charlotte Lab successfully implemented WNV NAT testing on the Panther Testing Platform on Monday...

Read More >

Procedure for pouring off samples if shipments will be extremely delayed

As winter weather continues to move through parts of the US, we would like to remind you it may be n...

Read More >

CTS to Implement the Grifols Procleix Ultrio Elite Assay Beginning June 1, 2020

Beginning June 1, 2020 all 5 CTS laboratories will being transitioning from the Grifols Procleix Ult...

Read More >

Assay History List

We have now added a new section called the "Assay History List" to the "At A Gla...

Read More >